1,658 results on '"Targan, Stephan R."'
Search Results
152. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-γ, in mucosal inflammation
153. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease
154. Epithelial endoplasmic reticulum stress orchestrates a protective IgA response
155. Epithelial endoplasmic reticulum stress orchestrates a protective IgA response
156. Sero-Reactivity to Microbial Components in Crohnʼs Disease Is Associated with Disease Severity and Progression, but not NOD2/CARD15 Genotype
157. Bacterial flagellin is a dominant antigen in Crohn disease
158. Role of mucosal T-cell-generated cytokines in epithelial cell injury
159. Neutrophil autoantibodies as disease markers for ulcerative colitis
160. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
161. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine
162. Lamina Propria Lymphocytes
163. Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Diseases
164. Sa1849 – Association of Serologic Markers and Surgery in Hispanics with Crohn’s Disease: A Cohort Study of the University of Puerto Rico Inflammatory Bowel Disease Genetic Research Consortium
165. 833a – Efficacy in Biologic-Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderatesevere Ulcerative Colitis: Unifi
166. 833 – Efficacy and Safety of Ustekinumab As Maintenance Therapy in Ulcerative Colitis: Week 44 Results from Unifi
167. Sa1096 – A Personalized Model to Assess Intestinal Permeability in IBD and Veoibd Patients Using Human Ipsc-Derived Intestinal and Colonic Organoids
168. Sa2040 – Vitamin B12 Malabsorption and Deficiency Following Restorative Proctocolectomy. A Systematic Review and Meta-Analysis
169. Su1879 – Novel Role for Death Receptor 3 (DR3) Expressed on Intestinal Epithelial Cells in Regulating Homeostatic Intestinal Permeability and Epithelial Cell Proliferation, As Well As Regeneration After Intestinal Mucosal Injury
170. Su1856 – A Pilot Study Comparing Postoperative Outcomes After Ustekinumab in Patients with Inflammatory Bowel Disease
171. 538 – A Blood Based Pre-Surgical Transcriptomic Signature Identifies a Severe Crohn's Disease Subtype and is Predictive of a Post Surgery Decrease in Pro-Inflammatory Pathway Activation
172. Tu1723 – Identification of Risk Factors Associated with Loss of Response to Ustekinumab in Crohn's Disease
173. 704 – Preoperative Serum Vedolizumab Levels Do Not Impact Postoperative Outcomes in Inflammatory Bowel Disease
174. Su1906 – Markers for Severe, Refractory Crohn’s Disease Derived from Cell Specific Gene Signatures
175. Sa1811 – Genotype and Posst-Operative Immunosuppression Impact Surgical Recurrence in Crohn's Disease
176. Tu1725 – Characterization of Patients with Delayed Response to Ustekinumab for Crohn's Disease
177. Tu1740 – Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Maintenance Study
178. Su1923 – Novel Associations of Platelets with Clinical and Serologic Variables in Crohn’s Disease (CD) and Ulcerative Colitis (UC)
179. Su1896 – Recombinant Rnaset2 Modulates Ifnγ Secretion: A Novel Potential Cd Therapeutic
180. 151 – Using Deeplearning and Genetic Bigdata to Predict Crohn's Disease
181. Tu1761 – Polygenic Risk Scores are Associated with Serological Markers Highlighting Disease Heterogeneity in Crohn's Disease (CD) and Ulcerative Colitis (UC)
182. Ileal Gene Expression Data from Crohn’s Disease Small Bowel Resections Indicate Distinct Clinical Subgroups
183. Epithelial endoplasmic reticulum stress orchestrates a protective IgA response
184. Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease
185. Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor (Alpha) for Crohn's Disease
186. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
187. Selected loss of tolerance evidenced by Crohn's disease–associated immune responses to auto- and microbial antigens
188. Biologic therapy of inflammatory bowel disease
189. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
190. A Short-Term Study of Chimeric Monoclonal Antibody CA2 to Tumor Necrosis Factor (alpha) for Crohn's Disease
191. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis
192. Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure.
193. Association of Antineutrophil Cytoplasmic Antibodies With Resistance to Treatment of Left-Sided Ulcerative Colitis: Results of a Pilot Study
194. CCR9–Positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease
195. ANCA Pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in crohn's disease
196. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease
197. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease
198. Ulcerative Colitis: A Genetically Heterogeneous Disorder Defined by Genetic (HLA Class II) and Subclinical (Antineutrophil Cytoplasmic Antibodies) Markers
199. Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative Colitis: A Multicenter Study
200. Tumor necrosis factor: Biology and therapeutic inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.